GSK’s shingles vaccine helps it shrug off Advair fears
UK drugmaker tightens full-year guidance towards upper end of expectations (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - October 31, 2018 Category: Pharmaceuticals Source Type: news

Glenmark inks licensing pact for generic Tiotropium Bromide dry powder inhaler in Western Europe
This is the second inhalation product in-licensed by Glenmark for the European market after Fluticasone/Salmeterol dry powder inhaler, the company said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - August 29, 2018 Category: Pharmaceuticals Source Type: news

FDA rejects Mylan ’s generic Advair again
Mylan announced that the FDA will not approve its Abbreviated New Drug Application for the generic version of GlaxoSmithKline's asthma drug, Advair Diskus, due to “minor deficiencies” in the application. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - June 15, 2018 Category: Pharmaceuticals Source Type: news

FDA Finds Deficiencies in Mylan's Generic Advair FDA Finds Deficiencies in Mylan's Generic Advair
Mylan NV said on Wednesday that U.S. health regulators were unable to approve its generic version of GlaxoSmithKline's blockbuster inhaled lung drug Advair for the second time, as they found"minor deficiencies" in the treatment.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 14, 2018 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

FDA rejects Mylan ’ s Advair generic in win for GSK
Shares in Mylan (NSDQ:MYL) dropped -5% yesterday after the pharmaceutical company revealed that it received the dreaded ‘complete response letter’ from the FDA, denying its application for a generic version of GlaxoSmithKline‘s (NYSE:GSK) blockbuster Advair respiratory drug. Canonsburg, PA-based Mylan noted that the CRL was due to “minor deficiencies” identified in its application and that it expects to wait until it receives the full notice on June 27 to determine how the rejection will impact its 2018 financial outlook. Get the full story at our sister site, Drug Delivery Business ...
Source: Mass Device - June 14, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Compliance Respiratory Wall Street Beat GlaxoSmithKline plc Mylan Novartis Source Type: news

FDA finds deficiencies in Mylan's generic Advair; shares fall
(Reuters) - Mylan NV said on Wednesday that U.S. health regulators were unable to approve its generic version of GlaxoSmithKline's blockbuster inhaled lung drug Advair, citing "minor deficiencies" with the drug. (Source: Reuters: Health)
Source: Reuters: Health - June 13, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

FDA finds deficiencies in Mylan's generic Advair
(Reuters) - U.S. drugmaker Mylan NV said on Wednesday that U.S. health regulators could not approve its generic version of GlaxoSmithKline's blockbuster inhaled lung drug, Advair, and cited "minor deficiencies" with the copycat version. (Source: Reuters: Health)
Source: Reuters: Health - June 13, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Bill would limit patient access to cheaper drugs
More than 25 million Americans suffer from asthma. The condition is well-known for restricting a patient ’s airway, making it difficult to breathe and often causing coughing and wheezing. In addition to putting the squeeze on a person’s lungs, asthma is also putting pressure on patients’ wallets, as the cost of inhalers has risen to about $5,000 a year. Doctors and patients were recently elated when a popular asthma medication went generic. Fluticasone/salmeterol is the first-ever generic asthma… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - May 16, 2018 Category: American Health Authors: Dr. John D. Bennett Source Type: news

Stronger pound weighs on GlaxoSmithKline revenues
UK drugmaker shares fall as it points to steeper decline in Advair sales (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - April 25, 2018 Category: Pharmaceuticals Source Type: news

GSK wins new reprieve as Hikma's generic Advair delayed again
(Reuters) - GlaxoSmithKline has won a further reprieve for its blockbuster Advair lung drug after U.S. regulators insisted Hikma Pharmaceuticals conduct a further clinical study evaluating its generic version of the drug. (Source: Reuters: Health)
Source: Reuters: Health - March 12, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Hikma plans new clinical study over generic Advair
(Reuters) - Hikma Pharmaceuticals Plc said on Monday it plans a new clinical study on its generic version of GlaxoSmithKline's popular lung drug Advair, as it looks to resolve an ongoing dispute with the Food and Drug Administration over plans to launch the drug in the U.S. (Source: Reuters: Health)
Source: Reuters: Health - March 12, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

GlaxoSmithKline Sees Light at End of Advair Tunnel GlaxoSmithKline Sees Light at End of Advair Tunnel
GlaxoSmithKline sees growth strengthening over the next few years as the drugmaker weathers increased competition in its core respiratory and HIV businesses that could cause earnings to dip this year.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 8, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

FDA rejects Novartis ’ Advair generic, leaving GSK without rival
GlaxoSmithKline (NYSE:GSK) was granted a temporary win today after Novartis‘ (NYSE:NVS) Sandoz unit reported that the FDA rejected its application for a generic version of the company’s blockbuster lung treatment, Advair. The regulatory agency reportedly told Novartis that it needs to submit additional clinical data before the FDA can make its final decision. Get the full story at our sister site, Drug Delivery Business News. The post FDA rejects Novartis’ Advair generic, leaving GSK without rival appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - February 8, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Compliance Respiratory Wall Street Beat GlaxoSmithKline plc Novartis sandoz Source Type: news

Drugmaker GSK wins fresh Advair reprieve as Novartis copy delayed
LONDON (Reuters) - GlaxoSmithKline has won another reprieve for its blockbuster Advair lung drug after U.S. regulators delayed approval of a generic copy from Novartis's Sandoz division. (Source: Reuters: Health)
Source: Reuters: Health - February 8, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

GlaxoSmithKline sees light at end of Advair tunnel
LONDON (Reuters) - GlaxoSmithKline sees growth strengthening over the next few years as the drugmaker weathers increased competition in its core respiratory and HIV businesses that could cause earnings to dip this year. (Source: Reuters: Health)
Source: Reuters: Health - February 7, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

AirDuo RespiClick Inhalation Powder (Fluticasone Propionate and Salmeterol) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 10, 2018 Category: Drugs & Pharmacology Source Type: news

Novartis' Ultibro ® Breezhaler® significantly improved COPD patients' lung function after direct switch from Seretide®
Novartis today announced positive results from the FLASH** study examining the safety and efficacy of directly switching chronic obstructive pulmonary disease (COPD) patients from Seretide® (salmeterol/fluticasone) 50/500 mcg to Ultibro® Breezhaler® (indacaterol/glycopyrronium) 110/50 mcg[1]. The study met the primary endpoint demonstrating that switching patients to Ultibro Breezhaler resulted in significantly improved lung function (trough FEV1)[1]. (Source: World Pharma News)
Source: World Pharma News - November 27, 2017 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

A Case of Worsening Dyspnea and Cough
Bob is a 72-year-old male, with a 40-pack-year smoking history. He quit about 8 years ago, when severe COPD was diagnosed. Until last year, he had been stable on his regimen of Advair 250/50 and Spiriva Handihaler, other than an occasional “bronchitis,” usually treated with an antibiotic and/or steroids. Over the past year or so, however, he has noticed a marked turn for the worse. He no longer can walk up the steps in his house without stopping and gasping for breath. (Source: ConsultantLive)
Source: ConsultantLive - November 27, 2017 Category: Internal Medicine Authors: Jonathan Ilowite, MD Tags: Respiratory Diseases Source Type: news

Europe approves GlaxoSmithKline's new triple lung drug
LONDON (Reuters) - Europe has approved GlaxoSmithKline's new three-in-one inhaler for chronic lung disease, which the group hopes will help it keep its lead in respiratory medicine despite falling sales of older drug Advair. (Source: Reuters: Health)
Source: Reuters: Health - November 16, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Hikma, Vectura in dispute with FDA over generic Advair
LONDON (Reuters) - Hikma and its partner Vectura are in dispute with the Food and Drug Administration over their plans to launch a generic copy of GlaxoSmithKline's popular lung drug Advair in the U.S. market, delaying any eventual approval. (Source: Reuters: Health)
Source: Reuters: Health - November 9, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

GlaxoSmithKline breathes easier as U.S. approves triple lung drug
LONDON (Reuters) - U.S. regulators have approved GlaxoSmithKline's three-in-one inhaler for chronic lung disease, a key new product for the group as it strives to keep its lead in respiratory medicine despite falling sales of the older drug Advair. (Source: Reuters: Health)
Source: Reuters: Health - September 19, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

A Case of Worsening Dyspnea and Cough
Bob is a 72-year-old male, with a 40-pack-year smoking history. He quit about 8 years ago, when severe COPD was diagnosed. Until last year, he had been stable on his regimen of Advair 250/50 and Spiriva Handihaler, other than an occasional “bronchitis,” usually treated with an antibiotic and/or steroids. Over the past year or so, however, he has noticed a marked turn for the worse. He no longer can walk up the steps in his house without stopping and gasping for breath. (Source: ConsultantLive)
Source: ConsultantLive - August 22, 2017 Category: Internal Medicine Authors: Jonathan Ilowite, MD Tags: Respiratory Diseases Source Type: news

Mylan revises earnings guidance, defers product launches to 2018
Mylan NV on Wednesday said it is deferring all major U.S. launches from its full-year 2017 financial guidance to 2018, citing ongoing challenges and the uncertain U.S. regulatory environment. As a result, the pharmaceutical giant expects to deliver total revenues ranging between $11.5 billion and $12.5 billion and adjusted earnigns per share between $4.30 and $4.70. The product launches include generic versions of Advair and Copaxone. Mylan (Nasdaq:MYL) included the announcement in its quarterly… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 9, 2017 Category: Pharmaceuticals Authors: Patty Tascarella Source Type: news

Novartiz unit Sandoz seeks FDA nod for generic Advair Diskus
Novartis (NYSE:NVS) unit Sandoz said today that the FDA has accepted the abbreviated new drug application for its generic version of Advair Diskus. The fluticasone propionate/salmeterol device is designed to treat asthma in patients ages 4 and older, as well as provide maintenance treatment of airflow obstruction and reduce exacerbations in patients with chronic obstructive pulmonary disease. Get the full story at our sister site, Drug Delivery Business News. The post Novartiz unit Sandoz seeks FDA nod for generic Advair Diskus appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - June 16, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Respiratory Wall Street Beat Amgen Novartis sandoz Source Type: news

US FDA issues CRL to Hikma ’s generic version of GSK’s Advair Diskus
Hikma Pharmaceuticals has received a complete response letter (CRL) from the US Food and Drug Administration (FDA) for the abbreviated new drug application (ANDA) of its generic version of GlaxoSmithKline's Advair Diskus (fluticasone propionate and s … (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - May 11, 2017 Category: Pharmaceuticals Source Type: news

GSK wins Advair reprieve as second generic falters
Hikma and Vectura shares fall as US FDA withholds approval for lung drug substitute (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - May 11, 2017 Category: Pharmaceuticals Source Type: news

GSK dodges bullet after another generic Advair competitor is denied
GlaxoSmithKline (NYSE:GSK) will not likely face generic competition to its lung drug Advair in the US this year. Yesterday, the FDA denied the application for a 2nd generic competitor. Hikma Pharmaceuticals (LON:HIK) disclosed today that the FDA decided not to approve its version of the inhaled asthma treatment, due to “major” problems with the application. This comes on the heels of Mylan‘s (NSDQ:MYL) announcement in March that the federal watchdog delayed approval of its Advair generic. Thanks to these 2 rejections, industry analysts believe that the threat of generic competition has...
Source: Mass Device - May 11, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Compliance Respiratory Wall Street Beat GlaxoSmithKline plc Hikma Pharmaceuticals PLC Mylan Source Type: news

GSK escapes Advair hit for now as second generic bid fails
LONDON (Reuters) - GlaxoSmithKline is likely to escape generic competition to its blockbuster lung drug Advair in the United States this year, after a second application for a cut-price equivalent form of the medicine was turned down by U.S. regulators. (Source: Reuters: Health)
Source: Reuters: Health - May 11, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Teva's new asthma inhaler poses first competition for GSK's Advair
(Reuters) - Teva Pharmaceutical Industries Ltd on Thursday launched an asthma inhaler that will be the first direct competition to GlaxoSmithKline's best-selling Advair. (Source: Reuters: Health)
Source: Reuters: Health - April 20, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Teva launches AirDuo RespiClick, generic inhaled asthma therapies
Teva Pharmaceutical (NYSE:TEVA) said today that it launched the AirDuo RespiClick inhalation therapy and its authorized generic in the U.S. for asthma patients who are uncontrolled on an inhaled corticosteroid. AirDuo RespiClick and the generic are fixed-dose combination therapies contained fluticasone propionate and salmeterol – the same active ingredients as Advair. The therapies are delivered using Teva’s breath-activated RespiClick inhaler. Get the full story at our sister site, Drug Delivery Business News. The post Teva launches AirDuo RespiClick, generic inhaled asthma therapies appeared first on Mas...
Source: Mass Device - April 20, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Pharmaceuticals Respiratory Wall Street Beat Teva Pharmaceuticals Source Type: news

FDA Declines to Approve Mylan's Generic Of GSK's Advair for Now FDA Declines to Approve Mylan's Generic Of GSK's Advair for Now
Mylan NV said on Wednesday the U.S. Food and Drug Administration declined to approve its generic version of GlaxoSmithKline Plc's blockbuster Advair asthma treatment, but provided no details of the agency's concerns or how long the product might be delayed.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - March 31, 2017 Category: Allergy & Immunology Tags: Pulmonary Medicine News Source Type: news

GSK's new CEO gets short-term win from generic Advair delay
LONDON (Reuters) - GlaxoSmithKline's new CEO Emma Walmsley, who takes over on April 1, has won a short-term reprieve from the threat of generic Advair with a delay in U.S. approval for Mylan's copy of the blockbuster lung inhaler. (Source: Reuters: Health)
Source: Reuters: Health - March 30, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

FDA declines to approve Mylan's generic of GSK's Advair for now
(Reuters) - Mylan NV said on Wednesday the U.S. Food and Drug Administration declined to approve its generic version of GlaxoSmithKline Plc's blockbuster Advair asthma treatment, but provided no details of the agency's concerns or how long the product might be delayed. (Source: Reuters: Health)
Source: Reuters: Health - March 29, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Mylan shares down -3% after FDA rejects Advair generic
Shares in Mylan (NSDQ:MYL) dropped -3% to $40.46 apiece today after the FDA rejected its Abbreviated New Drug Application for the generic version of GlaxoSmithKline‘s (NYSE:GSK) Advair Diskus. The Canonsburg, Penn.-based company said it is “in the process of reviewing this response and will provide an update on its application as soon as practicable once it has completed its review and discussed the FDA’s feedback with the agency.” Get the full story at our sister site, Drug Delivery Business News. The post Mylan shares down -3% after FDA rejects Advair generic appeared first on MassD...
Source: Mass Device - March 29, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Clearance Respiratory Wall Street Beat GlaxoSmithKline plc Mylan Source Type: news

FDA, Mylan silence on generic Advair may be good news for GSK
LONDON (Reuters) - A deadline for U.S. regulators to give a verdict on a generic copy of GlaxoSmithKline's blockbuster inhaled lung drug Advair has passed with no sign of approval, sparking speculation that a threat to GSK profits might be delayed. (Source: Reuters: Health)
Source: Reuters: Health - March 29, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

AirDuo RespiClick Inhalation Powder (Fluticasone Propionate and Salmeterol) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 8, 2017 Category: Drugs & Pharmacology Source Type: news

As Teva Wins U.S. Approval for GSK Advair Copy, Main Fight Yet to Come As Teva Wins U.S. Approval for GSK Advair Copy, Main Fight Yet to Come
Israel's Teva Pharmaceutical Industries has won U.S. approval to market a copy of GlaxoSmithKline's best-selling Advair inhaler, although the real battle is still to come.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - January 31, 2017 Category: Allergy & Immunology Tags: Pulmonary Medicine News Alert Source Type: news

Teva Announces FDA Approval of AirDuo RespiClick (fluticasone propionate and salmeterol) for Maintenance Treatment of Asthma
JERUSALEM--(BUSINESS WIRE) January 30, 2017 --Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved AirDuo RespiClick (fluticasone propionate and salmeterol... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 30, 2017 Category: Drugs & Pharmacology Source Type: news

As Teva wins U.S. approval for GSK Advair copy, main fight yet to come
LONDON (Reuters) - Israel's Teva Pharmaceutical Industries has won U.S. approval to market a copy of GlaxoSmithKline's best-selling Advair inhaler, although the real battle is still to come. (Source: Reuters: Health)
Source: Reuters: Health - January 30, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Advair HFA (Fluticasone Propionate and Salmeterol) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 22, 2016 Category: Drugs & Pharmacology Source Type: news

Advair Diskus, Advair HFA (fluticasone and salmeterol oral inhaler)
Title: Advair Diskus, Advair HFA (fluticasone and salmeterol oral inhaler)Category: MedicationsCreated: 1/22/2002 12:00:00 AMLast Editorial Review: 11/7/2016 12:00:00 AM (Source: MedicineNet Asthma General)
Source: MedicineNet Asthma General - November 7, 2016 Category: Respiratory Medicine Source Type: news

AstraZeneca, Bespak ink deal for metered-dose inhaler
AstraZeneca (NYSE:AZN) said last week that it inked a multi-year commercial supply deal with Consort Medical (LON:CSRT) subsidiary Bespak for its pressurized metered-dose inhaler technology. Bespak will supply inhaler valves and actuators for use with AstraZeneca’s inhaled aerosol treatment for chronic obstructive pulmonary disease. AstraZeneca won FDA approval in April for the aerosol, Bevespi Aerosphere (glycophrrolate and formoterol fumarate), indicated for long-term, maintenance therapy in patients with COPD. “We are delighted to have successfully concluded this agreement with AstraZeneca,” Consort Me...
Source: Mass Device - September 12, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Research & Development AstraZeneca plc Consort Medical Source Type: news

Advair Safety on Par With Monotherapy for Kids With Asthma (CME/CE)
(MedPage Today) -- But do all children benefit from combination therapy with a LABA? (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - August 31, 2016 Category: Allergy & Immunology Source Type: news

Novel LAMA/LABA Combo Shines for COPD (CME/CE)
(MedPage Today) -- Better than Advair for some measures in phase III trial (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - August 20, 2016 Category: Allergy & Immunology Source Type: news

Your inhaler’s watching you: drugmakers race for smart devices
(Reuters) – Makers of inhalers to treat asthma and chronic lung disease are racing to develop a new generation of smart devices with sensors to monitor if patients are using their puffers properly. Linked wirelessly to the cloud, the gadgets are part of a medical “Internet of Things” that promises improved adherence, or correct use of the medication, and better health outcomes. They may also hold the key to company profits in an era of increasingly tough competition. Drugmakers believe giving patients and doctors the ability to check inhaler use in this way could be a big help in proving the value of thei...
Source: Mass Device - July 20, 2016 Category: Medical Equipment Authors: MassDevice Tags: mHealth (Mobile Health) Patient Monitoring Respiratory AstraZeneca plc GlaxoSmithKline plc Novartis AG Qualcomm Source Type: news

Your inhaler ’ s watching you: drugmakers race for smart devices
(Reuters) – Makers of inhalers to treat asthma and chronic lung disease are racing to develop a new generation of smart devices with sensors to monitor if patients are using their puffers properly. Linked wirelessly to the cloud, the gadgets are part of a medical “Internet of Things” that promises improved adherence, or correct use of the medication, and better health outcomes. They may also hold the key to company profits in an era of increasingly tough competition. Drugmakers believe giving patients and doctors the ability to check inhaler use in this way could be a big help in proving the value of thei...
Source: Mass Device - July 20, 2016 Category: Medical Equipment Authors: MassDevice Tags: mHealth (Mobile Health) Patient Monitoring Respiratory AstraZeneca plc GlaxoSmithKline plc Novartis AG Qualcomm Source Type: news

Strong earnings help Consort Medical recover from hit by delay in Mylan approval
Consort Medical (LON:CSRT) said the impending launch of a generic Advair inhaler by Mylan (NSDQ:MYL) represents a significant opportunity for its Bespak drug delivery device unit, but analysts were less impressed after the FDA delayed its decision date for asthma therapy to March 28, 2017. That pushed CSRT shares down -1.9% to a $1.35 (941 pence) close yesterday on the London Stock Exchange, but investors pushed the stock up 4.9% to a $1.41 (987p) close today after Consort said it doubled the top line in fiscal 2016. Sales were up 50% to $396.4 million (£276.9 million) and pretax ea...
Source: Mass Device - June 17, 2016 Category: Medical Equipment Authors: Varun Saxena Tags: Drug-Device Combinations Pharmaceuticals Respiratory Asthma Consort Medical Mylan Inc. Source Type: news

In fight for GSK's Advair, generic firms step carefully on price
LONDON (Reuters) - Generic drugmakers, hoping for rich pickings from the launch of copies of GlaxoSmithKline's best-selling Advair inhaler in the United States next year, say they can win business without a race to the bottom on price. (Source: Reuters: Health)
Source: Reuters: Health - June 3, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

Advair Diskus (Fluticasone Propionate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 23, 2016 Category: Drugs & Pharmacology Source Type: news

fluticasone and salmeterol oral inhaler, Advair Diskus, Advair HFA
Title: fluticasone and salmeterol oral inhaler, Advair Diskus, Advair HFACategory: MedicationsCreated: 1/22/2002 12:00:00 AMLast Editorial Review: 5/18/2016 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - May 18, 2016 Category: Drugs & Pharmacology Source Type: news